Capital International Investors Adaptimmune Therapeutics PLC Transaction History

Capital International Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $4.54 Million - $8.42 Million	-1,321,200 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $833,040 - $3.14 Million	694,200 Added 110.72%	1,321,200 $3.59 Million
Q2 2019 Aug 14, 2019	BUY	$3.23 - $5.41 $752,590 - $1.26 Million	233,000 Added 59.14%	627,000 $2.52 Million
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $3.26 Million - $5.34 Million	394,000 New	394,000 $5.34 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $108M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.